Dilek BULUT, Aslı HAYKIR SOLAY, Merve Sefa SAYAR

VAN EĞİTİM VE ARAŞTIRMA HASTANESİNDEKİ HEMODİYALİZ HASTALARINDA HBV, HCV VE HİV SEROLOJİK İNDİKATÖRLERİ

AMAÇ: Bu çalışmada, kronik böbrek yetmezliği tanısıyla hemodiyalizuygulanan hastalarda; kan yoluyla bulaşan enfeksiyonlar incelenerekenfeksiyon kontrol programlarının etkinliğinin değerlendirilmesiamaçlanmıştır.GEREÇ VE YÖNTEM: Çalışmada 1 Ocak- 1 Ağustos 2018 tarihleriarasında rutin hemodiyaliz uygulanan hastaların dosyaları restrospektifolarak incelendi. Hastaların demografik özellikleri ve hastanemizmikrobiyoloji laboratuvarında macro ELİSA yöntemi ile çalışılanHBsAg, Anti-HBs, Anti-HCV ve Anti-HİV serolojileri kaydedildi.BULGULAR: Hemodiyaliz sonrası HBsAg ve Anti-HİV reaktifliğigelişen hasta bulunmamakta olup; Anti-HCV reaktifliği olan yedihasta saptandı. Anti-HCV reaktif hastaların beş yıldan daha uzundiyalize girdiği ve yaş ortalamalarının daha düşük olduğu saptandı(p

SEROLOGIC INDICATORS OF HBV, HCV AND HIV IN HEMODIALYSIS PATIENTS IN VAN TRAINING AND RESEARCH HOSPITAL

INTRODUCTION: It was aimed to examine the blood-borne infections in patients to whom hemodialysis is applied due to chronic renal failure and evaluating the effectiveness of infection control programs in this study. MATERIALS AND METHODS: Patients who underwent routine hemodialysis between January and August 2018 were included into the study. The study was designed as a retrospective. The blood samples taken from patients during their health screenings were tested with the macro ELISA method for HBsAg, Anti-HBs, AntiHCV and Anti-HIV observations at the microbiology laboratory and the clinical information was acquired from patient files. RESULTS: There were no patients who developed reactivity of chronic HBsAg and anti-HIV based on dialysis. One of eight AntiHCV reactive patients was not included in the analyses since the patient had the disease before undergoing dialysis. It was detected that Anti-HCV reactive patients underwent dialysis for more than five years and they had a lower mean age (p

PDF

___

1.)Bernieh B. Viral hepatitis in hemodialysis: An update. J. Transl. Intern. Med. 2015;3:93-105. DOI: 10.1515/jtim-2015-0018.
2.)Yadegarynia D, Hatamai H, Roodsari SR, Arab-mazar Z. Seroprevalence of hepatitis B , C and D viral among hemodialysis patients in Tehran. 2017;9:195–199. PMCID: PMC5719514.
3.)Temiz H, Kaya Ş, Berekatoğlu N, Temiz S, Danış R. Hemodiyaliz Hastalarında HBV, HCV ve HIV Seroprevalansı ve Hepatit B Aşılaması ile Oluşan Antikor Cevabının Değerlendirilmesi. Viral Hepatit Derg. 2013;19:140–143. Doi: 10.4274/Vhd.66375.
4.)Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK. Hepatitis C in hemodialysis patients. World J. Hepatol. 2015;7:548–558. DOI: 10.4254/wjh.v7.i3.548.
5.)Tozun N, Ozdoğan O, Cakaloglu Y et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21: 1020– 1026. DOI: https://doi.org/10.1016/j.cmi.2015.06.028.
6.)World Health Organization (WHO). http://apps.who.int/gho/ data/view.main.22100WHO?lang=en. Erişim tarihi: 18.12.2018.
7.)Mahboobi N, Porter SR, Karayiannis P, Alavian S. Dental Treatment as a Risk Factor for Hepatitis B and C Viral Infection . A Review of the Recent Literature.J Gastrointestin Liver Dis.2013; 22:79–86. PMID:23539395.
8.)Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World J. Gastroenterol.2017;23:151–166. DOI: 10.3748/wjg.v23.i1.151.
9.)İdilman R, Baykam N, Kaymakoğlu S et al. Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus. Turk J Gastroenterol. 2017;28:90–93. DOI: 10.5152/tjg.2017.21.
10.)Kaplan Ö, Bakıcı MZ, Çelik C, Kayataş M, Candan F. Cumhuriyet Üniversitesi Araştırma ve Uygulama Hastanesi Hemodiyaliz Ünitesi Hastalarının HBsAg ve Anti HCV Seropozitiflikleri. Viral Hepatit Derg. 2013;19(3):126–130. Doi: 10.4274/Vhd.88597.
11.)Tozun N, Ozdogan O, Cakaloğlu Y et al. Seroprevalance of hepatitis B and C infections in Turkey. Turkish J. Gastroenterol. 2017;28:147–148. DOI: 10.5152/tjg.2017.1710021.
12.)World Health Organization. Global Hepatitis Report 2017. 2017;(83):1-83.
13.)Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J. Hepatol. 2015;7:885–895. doi: 10.4254/wjh.v7.i6.885.
14.)Luma HN, Halle MP, Bagnaka Eloumou SAF et al. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses among haemodialysis patients in two newly opened centres in Cameroon. Pan Afr Med J. 2017;27:1–10. doi:10.11604/ pamj.2017.27.235.13121.
15.)Süleymanlar G, Ateş K, Seyahi N. Türkiye'de Nefroloji Diyaliz Ve Transplantasyon. Türk nefroloji derneği yayınları. Registry 2016. 2017:1-142.
16.)Terrault NA, Lok ASF, McMohan BJ et al. Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67:1560–1599. DOI:10.1002/hep.29800.
17.)Barnes S, Permanente K, Concepcion D et al. Guide to the Elimination of Infections in Hemodialysis, 2010. https://apic.org/ Resource_/EliminationGuideForm/7966d850-0c5a-48ae-9090- a1da00bcf988/File/APIC-Hemodialysis.pdf. Erişim Tarihi: 09.01.2018.
18.)Tosun S. Viral hepatitlerin ülkemizdeki değişen epidemiyolojisi. Ankem Derg. 2013; 27: 128–134.
19.)Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. Suppl. 2008;73:1-99. DOI:10.1038/ki.2008.81.
20.)Aygen B. Kan ve kan ürünleri transfüzyonu ile bulaşan enfeksiyonlar. ed: Doğanay M, Ünal S, ŞArdan-Çetinkaya Y. Türk Hastane Enfeksiyonları ve Kontrolü Derneği Hastane İnfeksiyonları. Baskı numarası:1, Bilimsel Tıp Yayınevi, 2013;1231-1251.
21.)Çopur-Çiçek A, Şahin OZ, Topaloğlu MK ve ark. The Seroprevalence of HBsAg, Anti-HBs ve Anti-HCV in Patients Applied Hemodialysis in Rize Province.Viral Hepatit Derg. 2013;19:15–18. Doi: 10.4274/Vhd.14633.
22.)Bozkurt I, Aygen B, Yıldız O, Gökahmetoğlu S. Bölgemizdeki hemodiyaliz hastalarında hepatit C virusu infeksiyonunun sıklığı ve epidemiyolojik özellikleri. Klimik Derg. 2011;24:167–172. doi:10.5152/kd.2011.41.
23.)Alp İ, Öztürk-Engin D, Oğuzoğlu N et al. Risk Factors Seroprevalence of Hepatitis B, C and D Virus in Hemodialysis patients in Istanbul. Mediterr J Infect Microb Antimicrob. 2014;3:1- 6. DOİ: 10.5578/mjima.6730.
24.)Daglar D, Ergani A, Demirbakan H ve ark. Hemodiyaliz hastalarında hepatit B ve hepatit C virüs enfeksiyonlarının serolojik ve moleküler yöntemlerle araştırılması. Mikrobiyol bul. 2014;48:143–150. PMID: 24506725.
25.)Mbaeyi C, Thompson ND. Hepatitis C virus screenig and management of seroconversions in hemodialysis facilities. Semin Dial. 2013 ; 26: 439–446. doi:10.1111/sdi.12097.
26.)Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect. Dis. 2012;12:1–8. doi: 10.1186/1471-2334-12-265.
27.)El-Ottol AEY, Elmanama AA, Ayesh BM. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine. Virol. J.2010;7:1-7. doi: 10.1186/1743-422X-7-210.
28.)Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: A systematic review of reports on outbreaks. Int. J. Artif. Organs. 2015; 38:471–480. DOI: 10.5301/ijao.5000437.
29.)Salvatierra K, Florez H. Prevalence of hepatitis B and C infections in hemodialysis patients. F1000Research.. 2016;5:1-14. Doi: 10.12688/f1000research.9068.1.